Welcome to our dedicated page for Cvrx SEC filings (Ticker: CVRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The CVRx, Inc. (NASDAQ: CVRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. CVRx is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular diseases, and its filings offer detailed insight into the Barostim platform, financial performance and risk profile.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand revenue trends, gross margin, operating expenses, cash and cash equivalents, long-term debt and stockholders’ equity, as well as narrative discussions of the business and risk factors. These filings also describe CVRx’s focus on Barostim for heart failure, regulatory approvals such as FDA approval and CE Mark, and the importance of reimbursement and coding decisions to the company’s operations.
Current reports on Form 8-K document material events, including the release of quarterly financial results and key corporate developments. For example, CVRx has filed 8-Ks to furnish earnings press releases and to disclose the appointment of a Chief Operating Officer, along with details about compensation arrangements. Such filings help investors track significant changes in management, financing and operating plans.
Through this page, users can also access information related to CVRx’s capital structure, including term loan agreements secured by substantially all of the company’s assets, as described in its public communications. Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly identify items such as revenue drivers, Barostim-related updates, reimbursement discussions and key risk disclosures. Real-time updates from EDGAR, along with AI explanations of 10-Ks, 10-Qs and 8-Ks, allow investors to follow how CVRx’s regulatory reporting reflects the evolution of its heart failure therapy business.
Johnson & Johnson, together with its subsidiary Johnson & Johnson Innovation – JJDC, Inc., reports beneficial ownership of 4,024,861 shares of CVRx, Inc. common stock, representing 15.4% of the class as of the measurement date. JJDC directly owns the shares, and Johnson & Johnson may be deemed to indirectly own them through its wholly owned subsidiary.
The ownership percentage is calculated against 26,210,109 CVRx common shares outstanding as of October 30, 2025, with the ownership position reported as of December 31, 2025. All voting and dispositive power over these shares is reported as shared rather than sole.
CVRx, Inc. entered into an Open Market Sale Agreement with Jefferies LLC that allows the company to offer and sell shares of its common stock in an at-the-market program. Under this arrangement, CVRx may issue shares with an aggregate offering amount of up to $50.0 million, from time to time, through Jefferies acting as sales agent.
Any sales will be made as at-the-market offerings under an effective Form S-3 shelf registration and related prospectus supplement. Jefferies will receive a commission of up to 3.0% of the gross proceeds from any shares sold, and CVRx will also cover certain related expenses. The company states that it intends to use any net proceeds primarily for working capital and general corporate purposes, and is not obligated to sell any specific amount under the agreement.
CVRx is offering up to $50,000,000 of common stock through an at-the-market program with Jefferies as sales agent. Shares may be sold from time to time on Nasdaq or other markets, with Jefferies earning a commission of up to 3% of the gross proceeds and treated as an underwriter. The company plans to use any net proceeds primarily for working capital and general corporate purposes.
At an illustrative price of $8.45 per share, CVRx assumes selling 5,917,159 shares, which would generate approximately $50.0 million in gross proceeds and increase net tangible book value from $1.68 to $2.87 per share. New investors in that scenario would see immediate dilution of $5.58 per share. As of September 30, 2025, CVRx had 26,193,733 shares outstanding, plus additional options, warrants and plan reserves that could add further dilution if exercised or issued.
CVRx, Inc. amended its term loan agreement on January 9, 2026, increasing total term loan availability by $50 million to up to $100 million, extending interest-only payments to four years from the closing date and pushing final maturity to May 9, 2031. The interest rate is now a floating rate equal to the greater of the prime rate or 6.75%, plus a margin of 2.65%, which falls to 2.00% after two consecutive quarters of positive adjusted EBITDA. The company immediately borrowed an additional $10 million, bringing total term loans outstanding to $60 million, and may draw a further $40 million if future revenue and market capitalization milestones are met.
CVRx expects fourth-quarter 2025 revenue of about $15.9–$16.1 million, up roughly 4–5% from $15.3 million a year earlier, and full-year 2025 revenue of about $56.5–$56.7 million, up 10–11% from $51.3 million in 2024. As of December 31, 2025, it had $75.7 million in cash and cash equivalents, 252 active implanting centers, and 53 U.S. sales territories.
The FDA granted an investigational device exemption for the BENEFIT-HF trial of the Barostim device in an expanded heart failure population. CVRx has applied to CMS for IDE Category B coverage; if approved, it plans to enroll across about 150 centers in the first half of 2026, with enrollment expected to complete within five years and a two-year follow-up. Net trial costs are expected at $20–$30 million, and a successful outcome could expand Barostim’s U.S. addressable market from roughly 339,000 to 983,000 patients, increasing the estimated sales opportunity from $10.5 billion to $30.5 billion.
Johnson & Johnson, as a reporting person and director of CVRx, Inc., filed an amended Form 4 to correct an earlier insider transaction report. Through its wholly owned subsidiary Johnson & Johnson Innovation - JJDC, Inc., it sold 16,000 shares of CVRx common stock on 11/25/2025 at a weighted average price of $10.03, and 6,337 shares on 11/26/2025 at a weighted average price of $10.03. The shares on 11/25/2025 were sold in multiple trades between $10.00 and $10.22, and on 11/26/2025 between $10.00 and $10.23. After these sales, 4,024,861 CVRx shares were reported as indirectly beneficially owned by Johnson & Johnson through JJDC. The amendment states the 11/25/2025 sale was omitted from the original filing due to an administrative oversight.
Johnson & Johnson filed a Form 4 reporting small open-market sales of CVRx, Inc. common stock held indirectly through its subsidiary Johnson & Johnson Innovation - JJDC, Inc. JJDC sold 500 CVRx shares on 11/21/2025 at a price of $10.00 per share and 2,200 shares on 11/24/2025 at a weighted average price of $10.06 per share. After these transactions, Johnson & Johnson, through JJDC, indirectly beneficially owned 4,047,198 CVRx common shares. The filing notes that the 11/24/2025 price reflects multiple trades between $10.00 and $10.10, and Johnson & Johnson undertakes to provide detailed trade breakdowns upon request.
Johnson & Johnson filed a Form 4 reporting open‑market sales of CVRx (CVRX)52,332 shares at a weighted average price of $10.21 on 11/06/2025 and 200 shares at $10.00 on 11/07/2025. After these transactions, J&J indirectly beneficially owned 4,050,898 CVRx shares through JJDC. Prices for the 11/06 trades ranged from $10.00 to $10.49 per share.
CVRx, Inc. filed a shelf registration statement on Form S-3 to offer and sell up to $150,000,000 of securities from time to time after effectiveness. The shelf covers common stock, preferred stock, debt securities, stock purchase contracts, warrants, rights, and units, with specific terms to be set in prospectus supplements.
Offerings may be made through underwriters, dealers, agents, or directly, at fixed, market-related, or negotiated prices. Use of proceeds will be described in the applicable supplement. CVRx’s common stock trades on Nasdaq under the symbol CVRX; on November 3, 2025, the last reported sale price was $10.36 per share.
CVRx, Inc. reported third‑quarter results showing steady top‑line growth and improved margins while remaining unprofitable. Revenue for the three months ended September 30, 2025 was $14.7 million, up 10% year over year, driven mainly by U.S. heart failure implants. Gross margin rose to 87% from 83% on higher average selling prices and manufacturing efficiencies.
Operating expenses were $25.0 million, yielding a loss from operations of $12.3 million. Net loss was $12.9 million (basic and diluted net loss per share $0.49). For the nine months, revenue reached $40.6 million (up 13%) with a net loss of $41.4 million.
Cash and cash equivalents were $85.1 million as of September 30, 2025, with $50.0 million of long‑term debt outstanding under the Innovatus loan. The company issued 543,462 shares via its ATM for gross proceeds of $9.5 million during the nine‑month period. CMS finalized the 2026 Medicare Physician Fee Schedule adding Category I CPT codes for Barostim, effective January 1, 2026.
CVRx, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the quarter ended September 30, 2025. The disclosure was made under Item 2.02, and the press release is included as Exhibit 99.1 and incorporated by reference.
The company states this information is being furnished, not filed, under the Exchange Act. CVRx’s common stock trades on the Nasdaq Global Select Market under the symbol CVRX.
FAQ
What is the current stock price of Cvrx (CVRX)?
What is the market cap of Cvrx (CVRX)?
